VYGR
Voyager Therapeutics, Inc.
Price Chart
Latest Quote
$3.43
-0.02 (-0.58%)
Current Price
| Previous Close | $3.45 |
| Open | $3.42 |
| Day High | $3.48 |
| Day Low | $3.35 |
| Volume | 461,284 |
Stock Information
| Shares Outstanding | 61.62M |
| Total Debt | $32.57M |
| Cash Equivalents | $116.34M |
| Revenue | $34.46M |
| Net Income | $-107.73M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $211.35M |
| EPS (TTM) | $-1.81 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $127.58M |
| Sales | $34.46M |
| Income | $-107.73M |
| Book/sh | $2.88 |
| Cash/sh | $1.89 |
| Employees | 141 |
Financial Ratios
| Quick Ratio | 7.16 |
| Current Ratio | 7.50 |
| Debt/Eq | 21.10 |
Returns & Margins
| ROA | -27.34% |
| ROE | -54.09% |
| Gross Margin | -236.81% |
| Operating Margin | -833.87% |
Ownership
| Insider Ownership | 14.84% |
| Institutional Ownership | 57.87% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.68 |
| P/S | 6.13 |
| P/B | 1.19 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $14.89 |
Technical Indicators
| SMA20 | $3.30 |
| SMA50 | $3.33 |
| SMA200 | $3.79 |
| RSI | 69.49 |
| ATR | 0.1429 |
| Shares Float | 44.47M |
| Short Float | 7.49% |
| Short Ratio | 6.95 |
| Volatility | 1.31 |
| Rel Volume | 1.06 |
Performance History
| Week | -0.29% |
| Month | +13.20% |
| Quarter | -9.50% |
| 6 Months | -17.35% |
| YTD | -14.89% |
| Year | +0.88% |
| 3 Years | -64.08% |
| 5 Years | +13.58% |
| 10 Years | -70.66% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-09-01 | $3.43 | 461,300 |
| 2026-08-31 | $3.45 | 395,600 |
| 2026-08-27 | $3.46 | 262,800 |
| 2026-08-26 | $3.46 | 279,300 |
| 2026-08-25 | $3.48 | 306,500 |
| 2026-08-24 | $3.44 | 406,000 |
| 2026-08-21 | $3.39 | 424,400 |
| 2026-08-20 | $3.32 | 717,000 |
| 2026-08-19 | $3.41 | 638,500 |
| 2026-08-18 | $3.30 | 658,000 |
| 2026-08-17 | $3.23 | 238,500 |
| 2026-08-14 | $3.27 | 306,200 |
| 2026-08-13 | $3.22 | 545,300 |
| 2026-08-12 | $3.20 | 376,100 |
| 2026-08-11 | $3.20 | 398,000 |
| 2026-08-10 | $3.17 | 393,300 |
| 2026-08-07 | $3.27 | 469,200 |
| 2026-08-06 | $3.13 | 421,000 |
| 2026-08-05 | $3.10 | 582,200 |
| 2026-08-04 | $3.13 | 429,000 |
| 2026-08-03 | $3.00 | 610,400 |
About Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
đ° Latest News
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates
Zacks âĸ 2026-08-06T23:10:27Z
Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimerâs?
Barrons.com âĸ 2026-07-13T06:00:00Z
Cramer to a 23-Year-Old: Buy It, but It Might Take a âLifetimeâ to Make Money
24/7 Wall St. âĸ 2026-07-02T13:33:43Z
Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside
Insider Monkey âĸ 2026-06-30T16:34:42Z
Here's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Situation
Simply Wall St. âĸ 2026-06-09T10:39:23Z
What Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy Programs
Insider Monkey âĸ 2026-05-20T12:35:51Z
Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-07T21:55:09Z
Voyager Therapeutics Conference: CEO Calls 2026 âYear of Tau,â Eyes BBB Capsid Clinic Debut
MarketBeat âĸ 2026-03-23T03:03:13Z
Does Voyager Therapeuticsâ (VYGR) Widening Annual Loss Redefine the Risk-Reward in Its Neurology Pipeline?
Simply Wall St. âĸ 2026-03-12T22:06:46Z
Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates
Zacks âĸ 2026-03-09T21:15:01Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $40,374,000 | $80,001,000 | $250,008,000 | $40,907,000 |
| Operating Revenue | $40,374,000 | $80,001,000 | $250,008,000 | $40,907,000 |
| Expenses | ||||
| Total Expenses | $172,218,000 | $163,288,000 | $127,994,000 | $91,744,000 |
| Other Income Expense | $1,649,000 | $622,000 | $3,000 | $2,653,000 |
| Other Non Operating Income Expenses | $1,649,000 | $622,000 | $3,000 | $2,653,000 |
| Net Non Operating Interest Income Expense | $10,618,000 | $18,328,000 | $11,721,000 | $1,792,000 |
| Total Other Finance Cost | $-10,618,000 | $-18,328,000 | $-11,721,000 | $-1,792,000 |
| Operating Expense | $172,218,000 | $163,288,000 | $127,994,000 | $91,744,000 |
| General And Administrative Expense | $37,544,000 | $35,920,000 | $35,822,000 | $30,980,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-119,721,000 | $-65,002,000 | $132,330,000 | $-46,408,000 |
| Net Interest Income | $10,618,000 | $18,328,000 | $11,721,000 | $1,792,000 |
| Normalized Income | $-119,721,000 | $-65,002,000 | $132,330,000 | $-46,408,000 |
| Net Income From Continuing And Discontinued Operation | $-119,721,000 | $-65,002,000 | $132,330,000 | $-46,408,000 |
| Total Operating Income As Reported | $-131,844,000 | $-83,287,000 | $122,014,000 | $-50,837,000 |
| Net Income Common Stockholders | $-119,721,000 | $-65,002,000 | $132,330,000 | $-46,408,000 |
| Net Income | $-119,721,000 | $-65,002,000 | $132,330,000 | $-46,408,000 |
| Net Income Including Noncontrolling Interests | $-119,721,000 | $-65,002,000 | $132,330,000 | $-46,408,000 |
| Net Income Continuous Operations | $-119,721,000 | $-65,002,000 | $132,330,000 | $-46,408,000 |
| Pretax Income | $-119,577,000 | $-64,337,000 | $133,738,000 | $-46,392,000 |
| Operating Income | $-131,844,000 | $-83,287,000 | $122,014,000 | $-50,837,000 |
| Per Share | ||||
| Diluted EPS | $-2.04 | $-1.13 | $2.97 | $-1.21 |
| Basic EPS | $-2.04 | $-1.13 | $3.08 | $-1.21 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-127,784,000 | $-78,556,000 | $126,455,000 | $-44,646,000 |
| Reconciled Depreciation | $4,060,000 | $4,731,000 | $4,441,000 | $6,191,000 |
| EBITDA (Bullshit earnings) | $-127,784,000 | $-78,556,000 | $126,455,000 | $-44,646,000 |
| EBIT | $-131,844,000 | $-83,287,000 | $122,014,000 | $-50,837,000 |
| Diluted Average Shares | $58,691,136 | $57,667,543 | $44,569,334 | $38,356,810 |
| Basic Average Shares | $58,691,136 | $57,667,543 | $43,020,747 | $38,356,810 |
| Diluted NI Availto Com Stockholders | $-119,721,000 | $-65,002,000 | $132,330,000 | $-46,408,000 |
| Tax Provision | $144,000 | $665,000 | $1,408,000 | $16,000 |
| Research And Development | $134,674,000 | $127,368,000 | $92,172,000 | $60,764,000 |
| Selling General And Administration | $37,544,000 | $35,920,000 | $35,822,000 | $30,980,000 |
| Other Gand A | $37,544,000 | $35,920,000 | $35,822,000 | $30,980,000 |
Fetched: 2026-08-09
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $196,081,000 | $299,760,000 | $236,320,000 | $59,020,000 |
| Total Assets | $252,281,000 | $393,050,000 | $351,281,000 | $159,356,000 |
| Total Non Current Assets | $49,594,000 | $116,241,000 | $31,597,000 | $34,857,000 |
| Other Non Current Assets | $2,736,000 | $2,874,000 | $1,593,000 | $1,515,000 |
| Investmentin Financial Assets | $5,244,000 | $65,704,000 | $0 | - |
| Current Assets | $202,687,000 | $276,809,000 | $319,684,000 | $124,499,000 |
| Other Current Assets | $2,277,000 | $2,874,000 | $2,628,000 | $4,233,000 |
| Prepaid Assets | $1,048,000 | $2,760,000 | $1,726,000 | $779,000 |
| Receivables | $2,915,000 | $4,491,000 | $84,455,000 | $639,000 |
| Accrued Interest Receivable | $1,003,000 | $2,311,000 | $964,000 | $382,000 |
| Accounts Receivable | $1,761,000 | $1,504,000 | $80,150,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $196,447,000 | $266,684,000 | $230,875,000 | $118,848,000 |
| Cash And Cash Equivalents | $65,300,000 | $71,367,000 | $68,802,000 | $98,959,000 |
| Cash Equivalents | $51,161,000 | $59,658,000 | $65,589,000 | $91,724,000 |
| Cash Financial | $14,139,000 | $11,709,000 | $3,213,000 | $7,235,000 |
| Non Current Prepaid Assets | - | - | - | - |
| Hedging Assets Current | - | - | - | - |
| Debt | ||||
| Total Debt | $36,499,000 | $43,726,000 | $20,294,000 | $23,126,000 |
| Long Term Debt And Capital Lease Obligation | $28,659,000 | $36,499,000 | $17,094,000 | $20,294,000 |
| Current Debt And Capital Lease Obligation | $7,840,000 | $7,227,000 | $3,200,000 | $2,832,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $56,200,000 | $93,290,000 | $114,961,000 | $100,336,000 |
| Total Non Current Liabilities Net Minority Interest | $29,659,000 | $43,502,000 | $50,453,000 | $27,745,000 |
| Other Non Current Liabilities | $1,000,000 | $1,000,000 | $1,000,000 | $1,001,000 |
| Non Current Deferred Liabilities | $0 | $6,003,000 | $32,359,000 | $6,450,000 |
| Current Liabilities | $26,541,000 | $49,788,000 | $64,508,000 | $72,591,000 |
| Current Deferred Liabilities | $1,590,000 | $24,394,000 | $42,881,000 | $59,377,000 |
| Payables And Accrued Expenses | $8,020,000 | $11,415,000 | $11,813,000 | $5,823,000 |
| Payables | $5,013,000 | $3,996,000 | $1,604,000 | $2,566,000 |
| Accounts Payable | $5,013,000 | $3,996,000 | $1,604,000 | $2,566,000 |
| Equity | ||||
| Common Stock Equity | $196,081,000 | $299,760,000 | $236,320,000 | $59,020,000 |
| Total Equity Gross Minority Interest | $196,081,000 | $299,760,000 | $236,320,000 | $59,020,000 |
| Stockholders Equity | $196,081,000 | $299,760,000 | $236,320,000 | $59,020,000 |
| Gains Losses Not Affecting Retained Earnings | $32,000 | $-407,000 | $-48,000 | $-219,000 |
| Other Equity Adjustments | $32,000 | $-407,000 | $-48,000 | $-219,000 |
| Retained Earnings | $-445,905,000 | $-326,184,000 | $-261,182,000 | $-393,512,000 |
| Other | ||||
| Ordinary Shares Number | $59,047,860 | $54,731,316 | $44,038,333 | $38,613,891 |
| Share Issued | $59,047,860 | $54,731,316 | $44,038,333 | $38,613,891 |
| Tangible Book Value | $196,081,000 | $299,760,000 | $236,320,000 | $59,020,000 |
| Invested Capital | $196,081,000 | $299,760,000 | $236,320,000 | $59,020,000 |
| Working Capital | $176,146,000 | $227,021,000 | $255,176,000 | $51,908,000 |
| Capital Lease Obligations | $36,499,000 | $43,726,000 | $20,294,000 | $23,126,000 |
| Total Capitalization | $196,081,000 | $299,760,000 | $236,320,000 | $59,020,000 |
| Additional Paid In Capital | $641,895,000 | $626,296,000 | $497,506,000 | $452,713,000 |
| Capital Stock | $59,000 | $55,000 | $44,000 | $38,000 |
| Common Stock | $59,000 | $55,000 | $44,000 | $38,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $0 | $6,003,000 | $32,359,000 | $6,450,000 |
| Long Term Capital Lease Obligation | $28,659,000 | $36,499,000 | $17,094,000 | $20,294,000 |
| Current Deferred Revenue | $1,590,000 | $24,394,000 | $42,881,000 | $59,377,000 |
| Current Capital Lease Obligation | $7,840,000 | $7,227,000 | $3,200,000 | $2,832,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $9,091,000 | $6,752,000 | $6,614,000 | $4,559,000 |
| Current Accrued Expenses | $3,007,000 | $7,419,000 | $10,209,000 | $3,257,000 |
| Investments And Advances | $5,244,000 | $65,704,000 | $0 | - |
| Available For Sale Securities | $5,244,000 | $65,704,000 | - | - |
| Net PPE | $41,614,000 | $47,663,000 | $30,004,000 | $33,342,000 |
| Accumulated Depreciation | $-19,151,000 | $-15,958,000 | $-15,038,000 | $-17,207,000 |
| Gross PPE | $60,765,000 | $63,621,000 | $45,042,000 | $50,549,000 |
| Leases | $6,850,000 | $6,487,000 | $7,106,000 | $12,554,000 |
| Other Properties | $51,476,000 | $54,800,000 | $35,311,000 | $35,662,000 |
| Machinery Furniture Equipment | $2,439,000 | $2,334,000 | $2,625,000 | $2,333,000 |
| Properties | $0 | $0 | $0 | $0 |
| Duefrom Related Parties Current | $151,000 | $676,000 | $3,341,000 | $257,000 |
| Other Short Term Investments | $131,147,000 | $195,317,000 | $162,073,000 | $19,889,000 |
| Construction In Progress | - | - | - | - |
Fetched: 2026-08-09
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-135,063,000 | $-18,831,000 | $74,663,000 | $-15,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-132,467,000 | $-15,310,000 | $77,919,000 | $-12,509,000 |
| Cash Flow From Continuing Operating Activities | $-132,467,000 | $-15,310,000 | $77,919,000 | $-12,509,000 |
| Operating Gains Losses | $141,000 | $510,000 | $178,000 | $377,000 |
| Investing Activities | ||||
| Capital Expenditure | $-2,596,000 | $-3,521,000 | $-3,256,000 | $-2,491,000 |
| Investing Cash Flow | $125,446,000 | $-94,859,000 | $-141,643,000 | $-7,339,000 |
| Cash Flow From Continuing Investing Activities | $125,446,000 | $-94,859,000 | $-141,643,000 | $-7,339,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $112,778,000 | $31,121,000 | $0 |
| Financing Cash Flow | $816,000 | $114,015,000 | $33,645,000 | $1,110,000 |
| Cash Flow From Continuing Financing Activities | $816,000 | $114,015,000 | $33,645,000 | $1,110,000 |
| Net Common Stock Issuance | $0 | $112,778,000 | $31,121,000 | $0 |
| Common Stock Issuance | $0 | $112,778,000 | $31,121,000 | $0 |
| Other | ||||
| End Cash Position | $68,036,000 | $74,241,000 | $70,395,000 | $100,474,000 |
| Beginning Cash Position | $74,241,000 | $70,395,000 | $100,474,000 | $119,212,000 |
| Changes In Cash | $-6,205,000 | $3,846,000 | $-30,079,000 | $-18,738,000 |
| Proceeds From Stock Option Exercised | $816,000 | $1,237,000 | $2,524,000 | $1,110,000 |
| Net Investment Purchase And Sale | $128,042,000 | $-91,338,000 | $-138,387,000 | $-4,848,000 |
| Sale Of Investment | $261,971,000 | $374,347,000 | $85,581,000 | $50,000,000 |
| Purchase Of Investment | $-133,929,000 | $-465,685,000 | $-223,968,000 | $-54,848,000 |
| Net PPE Purchase And Sale | $-2,596,000 | $-3,521,000 | $-3,256,000 | $-2,491,000 |
| Purchase Of PPE | $-2,596,000 | $-3,521,000 | $-3,256,000 | $-2,491,000 |
| Change In Working Capital | $-28,761,000 | $34,859,000 | $-66,557,000 | $20,471,000 |
| Change In Other Working Capital | $-28,807,000 | $-44,842,000 | $9,414,000 | $23,731,000 |
| Change In Other Current Liabilities | $-7,227,000 | $-3,320,000 | $-2,833,000 | $-3,922,000 |
| Change In Other Current Assets | $4,871,000 | $4,597,000 | $1,975,000 | $3,310,000 |
| Change In Payables And Accrued Expense | $-1,483,000 | $-260,000 | $8,045,000 | $-1,156,000 |
| Change In Accrued Expense | $-2,500,000 | $-2,652,000 | $9,007,000 | $-3,148,000 |
| Change In Payable | $1,017,000 | $2,392,000 | $-962,000 | $1,992,000 |
| Change In Account Payable | $1,017,000 | $2,392,000 | $-962,000 | $1,992,000 |
| Change In Prepaid Assets | $3,617,000 | $-2,627,000 | $76,000 | $-1,967,000 |
| Change In Receivables | $268,000 | $81,311,000 | $-83,234,000 | $475,000 |
| Changes In Account Receivables | $-257,000 | $78,646,000 | $-80,150,000 | $0 |
| Stock Based Compensation | $14,787,000 | $14,785,000 | $11,153,000 | $9,344,000 |
| Asset Impairment Charge | $0 | $2,776,000 | $0 | $0 |
| Amortization Of Securities | $-2,973,000 | $-7,969,000 | $-3,626,000 | $-16,000 |
| Depreciation Amortization Depletion | $4,060,000 | $4,731,000 | $4,441,000 | $6,191,000 |
| Depreciation And Amortization | $4,060,000 | $4,731,000 | $4,441,000 | $6,191,000 |
| Depreciation | $4,060,000 | $4,731,000 | $4,441,000 | $6,191,000 |
| Gain Loss On Sale Of PPE | $141,000 | $510,000 | $178,000 | $377,000 |
| Net Income From Continuing Operations | $-119,721,000 | $-65,002,000 | $132,330,000 | $-46,408,000 |
| Other Non Cash Items | - | - | - | $-2,468,000 |
| Sale Of PPE | - | - | - | - |
Fetched: 2026-08-09